ALK-Abelló A/S (ALK-B) - Stock Price & Dividends
Exchange: Copenhagen Exchange • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0061802139
ALK-Abelló A/S is a leading allergy solutions company that operates in Europe, North America, and internationally, dedicated to providing innovative solutions for people suffering from allergies.
The company's product portfolio is extensive, featuring a range of treatments for allergic rhinitis and allergic asthma, including GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK. These products are designed to combat various allergies, such as grass, ragweed, house dust mite, Japanese cedar, tree, and food allergies, and are available in different forms, including injections, sublingual drops, and tablets.
ALK-Abelló A/S goes beyond just treatment, offering a comprehensive consumer healthcare solution through its Digital eco-system. This platform connects and engages with allergy sufferers throughout their disease journey, providing tools, guidance, and relief. The platform also offers e-commerce solutions, making it easier for patients to access the support they need.
In addition to its treatment and consumer healthcare solutions, the company provides diagnostic allergy solutions, including skin prick tests and blood tests. In emergency situations, ALK-Abelló A/S also offers adrenaline injections for the treatment of acute life-threatening allergic reactions, including Anaphylaxis.
The company has formed a strategic collaboration with Torii Pharmaceutical Co., Ltd. to develop, market, and distribute an allergy immunotherapy tablet for the treatment of grass pollen allergy. With a rich history dating back to 1923, ALK-Abelló A/S is headquartered in Horsholm, Denmark, and continues to innovate and improve the lives of people with allergies.
Drawdown (Underwater) Chart
ALK-B Stock Overview
Market Cap in USD | 3,959m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception |
ALK-B Stock Ratings
Growth 5y | 4.56 |
Fundamental | 52.6 |
Dividend | 3.21 |
Rel. Performance vs Sector | 5.18 |
Analysts | - |
Fair Price Momentum | 154.12 DKK |
Fair Price DCF | 40.08 DKK |
ALK-B Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 64.1% |
ALK-B Growth Ratios
Growth 12m | 77.36% |
Growth Correlation 12m | 69% |
Growth Correlation 3m | 11% |
CAGR 5y | 15.92% |
CAGR/Mean DD 5y | 0.76 |
Sharpe Ratio 12m | 1.87 |
Alpha vs SP500 12m | 49.82 |
Beta vs SP500 5y weekly | 0.97 |
ValueRay RSI | 85.42 |
Volatility GJR Garch 1y | 37.42% |
Price / SMA 50 | 14.98% |
Price / SMA 200 | 47.82% |
Current Volume | 183.6k |
Average Volume 20d | 334k |
External Links for ALK-B Stock
As of May 19, 2024, the stock is trading at DKK 152.00 with a total of 183,641 shares traded.
Over the past week, the price has changed by -0.85%, over one month by +20.44%, over three months by +18.56% and over the past year by +77.36%.
According to ValueRays Forecast Model, ALK-B ALK-Abelló A/S will be worth about 171.7 in May 2025. The stock is currently trading at 152.00. This means that the stock has a potential upside of +12.96%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 135 | -11.2 |
Analysts Target Price | - | - |
ValueRay Target Price | 171.7 | 13.0 |